(redirected from Cilostazol)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
References in periodicals archive ?
4 Survey on Market Share of Major Cilostazol Manufacturers in China, 2010-2014
In the study, 2757 patients who had already suffered a stroke were split into two roughly equal groups - one of which was given aspirin and the other cilostazol for as long as five years.
Seven days before their operation they began receiving the drug cilostazol (100 mg) twice per day or alternatively 50 mg if they are undergoing high-bleeding-risk surgery or are intolerant of the full dose.
Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study.
STOCKHOLM -- Adding cilostazol to a standard, dual-antiplatelet therapy regimen significantly cut platelet reactivity in patients, especially in those with diabetes, in a controlled study with 80 patients.
Combined inhibitor of CYP 2C19 and 3A4 may raise esomeprazole levels NEXIUM may increase systemic exposure of cilostazol and an active metabolite.
Tenders are invited for Supply of Generic Medicines, Co-Atenolol 100mg, Haloperidol Inj, Ramipril & Hydrochlorothiazide, Spiranilactone 25mg, Bacillus Clausii, Cilostazol 50mg, Doxofylline 400mg, Glimepiride 1 Mg, Isotretinoin 10 Mg, Lornithinelaspartate, Racecadotril, Stiloz 12.
Aspirin, P2Y12 blockers, cilostazol, PAR-1 blockers and emerging antiplatelet therapies: can biomarkers guide clinical development and practice?
SAN ANTONIO -- The antiplatelet drug cilostazol appears to surpass aspirin in secondary stroke prevention with less risk of bleeding, based on the results of a Japanese study of more than 2,700 stroke patients.
The antiplatelet drug cilostazol was better than aspirin in preventing a recurrent stroke in a Japanese trial.
NEW ORLEANS--Adding cilostazol to a standard, dual-antiplatelet regimen following the placement of either drugeluting or bare-metal stents led to less restenosis, late loss, and need for revascularization in a meta-analysis of eight small, randomized trials.
The GWQ Service Plus AG intends to carry out a Europe-wide, open tendering process for preparations containing the active ingredients cilostazol, Epleneron, pregabalin and the active ingredient combination with salmeterol + fluticasone with contract start to 01/07/2015.